Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 5/20 | 0.61 |
| ▸ | NR1H4 | Q96RI1 | 3/20 | 0.61 |
| ▸ | IDO1 | P14902 | 2/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.44 |
| ▸ | KDM4A | O75164 | 1/20 | 0.43 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 2/20 | 0.42 |
| ▸ | HTT | P42858 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | GLA | P06280 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | XBP1 | P17861 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5413105 | 0.89 | EPHX2 (0.48) | EPHX2NR1H4IDO1ALDH1A1KDM4A | |
| SCHEMBL6676049 | 0.86 | IDO1 (0.55) | EPHX2NR1H4IDO1ALDH1A1TRPV1 | |
| SCHEMBL13385350 | 0.86 | EPHX2 (0.47) | EPHX2NR1H4IDO1KDM4AKCNA5 | |
| SCHEMBL4599344 | 0.84 | KDM4A (0.44) | EPHX2NR1H4IDO1ALDH1A1KDM4A | |
| SCHEMBL13780329 | 0.84 | EPHX2 (0.50) | EPHX2NR1H4IDO1ALDH1A1KDM4A | |
| SCHEMBL507690 | 0.83 | AAK1 (0.49) | EPHX2NR1H4IDO1ALDH1A1KDM4A | |
| SCHEMBL4597727 | 0.83 | AKR1B1 (0.46) | EPHX2NR1H4IDO1KDM4AKCNA5 | |
| SCHEMBL23762070 | 0.83 | KCNA5 (0.46) | EPHX2NR1H4IDO1KDM4AKCNA5 | |
| SCHEMBL12330489 | 0.83 | KDM4A (0.45) | EPHX2NR1H4IDO1KDM4AKCNA5 | |
| SCHEMBL654820 | 0.83 | KDM4A (0.45) | EPHX2NR1H4IDO1ALDH1A1KDM4A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250179072-A1 | TRICYCLIC AKR1C3 DEPENDENT KARS INHIBITORS | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC. | 2025-06-05 | — | — | US | disclosed |
| WO-2025049326-A1 | TRICYCLIC HETEROAROMATIC INHIBITORS OF KLK5 | BIOCRYST PHARMACEUTICALS, INC. (US) | 2025-03-06 | — | — | WO | disclosed |
| CN-114206870-B | Tricyclic AKR1C 3-dependent KARS inhibitors | 诺华股份有限公司 | 2024-09-03 | — | — | CN | disclosed |
| US-20240262827-A1 | TRICYCLIC AKR1C3 DEPENDENT KARS INHIBITORS | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC. | 2024-08-08 | — | — | US | disclosed |
| EP-4349839-A2 | TRICYCLIC AKR1C3 DEPENDENT KARS INHIBITORS | Novartis AG (CH) | 2024-04-10 | — | — | EP | disclosed |
| EP-4013500-B1 | TRICYCLIC AKR1C3 DEPENDENT KARS INHIBITORS | NOVARTIS AG (CH) | 2023-10-25 | — | — | EP | disclosed |
| US-20220315582-A1 | TRICYCLIC AKR1C3 DEPENDENT KARS INHIBITORS | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC. | 2022-10-06 | — | — | US | disclosed |
| EP-4013500-A1 | TRICYCLIC AKR1C3 DEPENDENT KARS INHIBITORS | Novartis AG (CH) | 2022-06-22 | — | — | EP | disclosed |
| US-20090182140-A1 | Alicyclic Heterocyclic Compound | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2009-07-16 | — | — | US | disclosed |
| US-7456195-B2 | Phenylglycinamide and pyridylglycinamide derivatives useful as anticoagulants | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-11-25 | — | — | US | disclosed |
| US-7456195-B2 | Phenylglycinamide and pyridylglycinamide derivatives useful as anticoagulants | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-11-25 | — | — | US | disclosed |
| EP-1970373-A1 | ALICYCLIC HETEROCYCLIC COMPOUND | Mitsubishi Tanabe Pharma Corporation (JP) | 2008-09-17 | — | — | EP | disclosed |
| EP-1910298-A2 | PHENYLGLYCINAMIDE AND PYRIDYLGLYCINAMIDE DERIVATIVES USEFUL AS ANTICOAGULANTS | Brystol-Myers Squibb Company (US) | 2008-04-16 | — | — | EP | disclosed |
| US-7262211-B2 | Aromatic heterocyclic non-covalent inhibitors of urokinase and blood vessel formation | DENDREON CORPORATION (US) | 2007-08-28 | — | — | US | disclosed |
| WO-2007002313-A2 | PHENYLGLYCINAMIDE AND PYRIDYLGLYCINAMIDE DERIVATIVES USEFUL AS ANTICOAGULANTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-01-04 | — | — | WO | disclosed |
| US-20070003539-A1 | Phenylglycinamide and pyridylglycinamide derivatives useful as anticoagulants | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-01-04 | — | — | US | disclosed |
| US-20070003539-A1 | Phenylglycinamide and pyridylglycinamide derivatives useful as anticoagulants | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-01-04 | — | — | US | disclosed |
| US-20030207842-A1 | Aromatic heterocyclic non-covalent inhibitors of urokinase and blood vessel formation | DENDREON PHARMACEUTICALS LLC | 2003-11-06 | — | — | US | disclosed |
| WO-2003048127-A1 | AROMATIC HETEROCYCLIC NON-COVALENT INHIBITORS OF UROKINASE AND BLOOD VESSEL FORMATION | CORVAS INTERNATIONAL, INC. (US) | 2003-06-12 | — | — | WO | disclosed |
| WO-2002014349-A2 | NON-COVALENT INHIBITORS OF UROKINASE AND BLOOD VESSEL FORMATION | CORVAS INTERNATIONAL, INC. (US) | 2002-02-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030207842-A1 | Aromatic heterocyclic non-covalent inhibitors of urokinase and blood vessel formation | PLAT, PLAU, SERPINE1 | EPHX2 1246/4885NR1H4 4003/4885IDO1 1219/4885 |
| US-20220315582-A1 | TRICYCLIC AKR1C3 DEPENDENT KARS INHIBITORS | AKR1C2, AKR1B1, AKR1C1 | EPHX2 2391/4885NR1H4 129/4885IDO1 3752/4885 |
| US-20090182140-A1 | Alicyclic Heterocyclic Compound | CCR4, CCR1, HRH4 | EPHX2 265/4885NR1H4 51/4885IDO1 260/4885 |
| US-20070003539-A1 | Phenylglycinamide and pyridylglycinamide derivatives useful as anticoagulants | F12, F11, F7 | EPHX2 1136/4885NR1H4 1443/4885IDO1 2033/4885 |
| US-20250179072-A1 | TRICYCLIC AKR1C3 DEPENDENT KARS INHIBITORS | AKR1C2, AKR1B1, AKR1C1 | EPHX2 2391/4885NR1H4 129/4885IDO1 3752/4885 |
| US-20240262827-A1 | TRICYCLIC AKR1C3 DEPENDENT KARS INHIBITORS | AKR1C2, AKR1B1, AKR1C1 | EPHX2 2391/4885NR1H4 129/4885IDO1 3752/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.